Ralf Bargou

from Wikipedia, the free encyclopedia

Ralf Christian Bargou (born August 2, 1961 in Sigmaringen ) is a German hematologist and oncologist and professor at the Julius Maximilians University of Würzburg .

Life

Bargou studied biology at the Ruprecht-Karls-Universität Heidelberg from 1982 to 1988 and obtained a diploma in biochemistry , genetics and organic chemistry . In 1987 he also began studying human medicine in Heidelberg , which he completed in 1992 with the state examination. In 1993 he received his doctorate on the subject of "The synaptophysin gene in rats and humans is specifically transcribed in neuroendocrine cells". After a short time as a research assistant at the Max Delbrück Center for Molecular Medicine in Berlin , he took over the leadership of a working group there and was also an assistant doctor at the Charité of the Humboldt University in Berlin . In 2001 Bargou completed his habilitation on the subject of "The importance of apoptosis resistance mechanisms for the pathogenesis and therapy of malignant lymphomas" and was appointed senior physician at the Charité in the same year .

From 2005 to 2011 Bargou headed the focus on hematology and internal oncology at the University Hospital Würzburg , where he was appointed to the W2 professorship in hematology and oncology one year later . Since 2011 Bargou has been W3 Professor and Chair for Translational Oncology and Director of the Comprehensive Cancer Center Mainfranken at the University Medical Center Würzburg. Furthermore, he is the spokesman for the oncological center there and heads the interdisciplinary Early Clinical Trial Unit .

Act

Bargou leads several clinical studies in the field of oncology as Principal Investigator and, among other things, heads a sub-area of ​​"Transregio 17", a project of the German Research Foundation . A major focus of research is in the area of ​​immune oncology and the development of so-called BiTE antibodies. Bargou was instrumental in the development of the bispecific antibody blinatumomab , for which he received the Paul Martini Prize in 2009 and the Investor of the Year Award in 2016. Another important contribution made by Bargou lies in the development of targeted therapies for residual molecular disease in acute lymphoblastic leukemia.

Web links

Individual evidence

  1. ↑ a b c d Paul Martini Foundation: Curriculum Vitae by Ralf Bargou (PDF; 244 kB), accessed on February 9, 2016.
  2. ↑ DNB, catalog of the German National Library: The synaptophysin gene from rats and humans is specifically transcribed in neuroendocrine cells , accessed on February 9, 2016.
  3. ↑ DNB, Catalog of the German National Library: The Importance of Apoptosis Resistance Mechanisms for the Pathogenesis and Therapy of Malignant Lymphomas , accessed on February 9, 2016.
  4. ↑ Julius-Maximilians-Universität Würzburg: Comprehensive Cancer Center Mainfranken - About Us ( Memento of the original from February 9, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , accessed February 9, 2016. @1@ 2Template: Webachiv / IABot / www.ccc.uni-wuerzburg.de
  5. ↑ Transregio 17: Ralf Bargou , accessed on February 9, 2016.
  6. ↑ Paul Martini Foundation: Better treatment of sepsis and lymph node cancer: Clinical researchers pave the way , accessed on February 9, 2016.
personal data
SURNAME Bargou, Ralf
ALTERNATIVE NAMES Bargou, Ralf Christian (full name)
BRIEF DESCRIPTION German physician and university professor
DATE OF BIRTH 2nd August 1961
PLACE OF BIRTH Sigmaringen